Bizot et al. Appl. No. 10/551.218

## Listing of Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

(Currently amended) A homogenous oral suspension comprising a beverage
consisting of apple juice and a mixture consisting of an effective amount of tegaserod or a
pharmaceutically acceptable salt thereof in the form of at least one of a powder, a
granulate, a grind, and a pulver of particles suspended therein, wherein the suspension
provides a partitioning of the effective amount a dose of tegaserod or pharmaceutically
acceptable salt thereof.

Claims 2-7 (Canceled).

- (Currently amended) The oral suspension of claim claim 5; wherein the erushed tablet is one crushed tablet comprising effective amount of tegaserod comprises a crushed tablet comprising 6 mg tegaserod maleate.
- (Currently amended) The oral suspension of claim 5<sub>ix</sub> wherein the erushed tablet is ene-crushed tablet comprising effective amount of tegaserod comprises a crushed tablet comprising 2 mg tegaserod maleate.

Claims 10-12, (Canceled).

13. (Currently amended) The oral suspension of claim 1; comprising 10 to 100 ml of the beverage consisting essentially of the apple juice.

Claims 14 -15. (Canceled).

16. (New) A method of administering a partitionable dose of tegaserod comprising administering by oral ingestion an amount of a homogenous suspension, the suspension comprising an effective amount of tegaserod maleate, or a pharmaceutically acceptable

Bizot et al. Appl. No. 10/551,218

salt thereof, in suspension with apple juice, wherein the amount ingested provides a partitioned dose of the effective amount of tegaserod.

17. (New) The method of Claim 16, wherein the effective amount of tegaserod comprises 2 mg or 6 mg of tegaserod maleate.